To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
News
Researchers from the SCBM have participated in the optimization of a bio-inspired catalyst anode developed by teams from IRIG (CEA, Grenoble). In particular, they have contributed to the fine control of the catalyst surface concentration.
Two researchers of UNICOG/NeuroSpin show that a gated recurrence model of neural networks would allow to make efficient and simple predictions, like our brain, in different environments. In addition to being biologically plausible, this model would be generalizable.
Using data from the UK Biobank, the world's largest general population imaging-genetics cohort, a collaboration led by a team at BAOBAB (NeuroSpin) has identified genes involved in the genetic architecture of language functional connectivity. These genes could be a priority for studying natural language.
Metaproteomics provides valuable snapshots of the functional state of microbiota. But the protocols used are still very diverse and the results not always easily comparable. The actors of the discipline, including the LI2D (Marcoule), are organizing themselves to be able to make the technique even more powerful.
A NeuroSpin team (BAOBAB) has tested a signal denoising method dedicated to very high field (7T) functional MRI. It is based on the weighted combination of images from each reception channel of the radio frequency coil, a combination that optimizes the stability of the signal over time.
A NeuroSpin team has exploited data on mental health and brain developmental disorders of subjects in the Healthy Brain Network cohort. It established a link between certain symptoms, precursors of possible mood disorders, and structural changes in the developing brain in more than 650 young people.
Thanks to recent developments in cryo-electron microscopy, a study led by a team from the I2BC reveals, at the atomic scale, the unsuspected structural complexity of lanreotide nanotubes, a drug used in the treatment of acromegaly and some neuro-endocrine cancers.
In a study conducted by a team from the Institut Curie, researchers from the CEA-Joliot (B3S/I2BC department) have modeled in silico protein-protein interactions and thus contributed to establish at the molecular level the mechanisms that coordinate the pairing and recombination of homologous chromosomes during meiosis.
A collaboration initiated in 2017 between AP-HP (Bichat Hospital), Paris-Saclay University (Inserm 1193) and the Laboratoire d’Études du Métabolisme des Médicaments (LEMM/SPI/DMTS), leading to 4 publications in 2021, is advancing knowledge on the origin of certain congenital disorders of glycosylation, through the identification of specific biochemical biomarkers.
European research teams, including one from the CEA's Joliot Institute, have analyzed the blood lipidome of patients with cirrhosis. They highlight specific biomarkers of the different stages of the disease.
Top page
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.